Actively Recruiting

Phase Not Applicable
Age: 55Years +
All Genders
NCT05977088

Prediction of Effectiveness of rTMS Application in Alzheimer's Patients

Led by Istanbul Medipol University Hospital · Updated on 2025-05-02

40

Participants Needed

1

Research Sites

201 weeks

Total Duration

On this page

Sponsors

I

Istanbul Medipol University Hospital

Lead Sponsor

B

Bezmialem Vakif University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Since pharmacological methods are insufficient in the treatment processes of Alzheimer's disease, non-pharmacological methods such as Transcranial Magnetic Stimulation (TMS) have started to be tried as a treatment option as in other neurological and psychiatric diseases. Repeated (rTMS) offers a potential treatment pathway for neurological and psychiatric illnesses. rTMS benefit rate may vary depending on many factors such as the region where it is applied, the progression and the disease degree. The possible effects of TMS on Alzheimer's pathophysiology and modification of disease process (neuroprotective, anti-inflammatory and antioxidant) will also be revealed through blood samples taken from patients before and after treatment. These approaches also constitute the original value of our study.

CONDITIONS

Official Title

Prediction of Effectiveness of rTMS Application in Alzheimer's Patients

Who Can Participate

Age: 55Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with clinical Alzheimer's Disease using NINCDS-ADRDA criteria
  • Age over 55 years
  • Clinical Dementia Rating Scale (CDR) score between 1 and 2
  • No other diseases affecting cognitive functions
  • Volunteer to participate in the study
Not Eligible

You will not qualify if you...

  • Participant or relative does not give consent
  • Unable to participate in entire study procedures (e.g., living in another city)
  • History of head trauma with alcohol or substance abuse
  • Severe stroke or other neurological sequelae disease
  • Metal implant on the head, pacemaker, or contraindications for TMS
  • Use of investigational drugs or neuromodulation treatments (e.g., tDCS, TMS) targeting Alzheimer's disease within 1 month before or during the study, except standard treatments such as acetylcholine esterase inhibitors and memantine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medipol University Hospital

Istanbul, Turkey (Türkiye), 34214

Actively Recruiting

Loading map...

Research Team

L

Lutfu Hanoglu, Prof. DR. MD

CONTACT

C

Cennet Sena Parlatan, PhD Cand

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here